Penumbra, a company set to join Boston Scientific in a $14.5 billion acquisition, has launched a clinical trial to evaluate its clot-removal technology in a specific stroke subgroup. The study focuses on patients with M2 occlusions, a type of blockage in the middle cerebral artery that affects 3% to 7% of acute ischemic stroke cases annually. The trial aims to determine whether mechanical thrombectomy—a procedure to remove blood clots—can improve outcomes for these patients.
Targeting a Niche in Stroke Care
M2 occlusions occur in a segment of the middle cerebral artery, a critical blood vessel in the brain. Blockages here are less common than those in larger arteries but still affect an estimated 21,000 to 66,000 patients yearly in the U.S.
Previous research, including a 2023 study on Medtronic’s Solitaire device, found that endovascular treatments for medium-vessel occlusions did not significantly outperform standard care. These findings raised concerns about the effectiveness of such procedures for M2 blockages.
Penumbra’s trial will enroll up to 250 participants across 40 sites. Half will receive medical management alone, while the other half will get treatment with the company’s RED reperfusion catheter portfolio. This includes the Thunderbolt device, which uses computer-assisted vacuum thrombectomy to remove clots.
Device Authorization and Clinical Context
Thunderbolt recently received regulatory approval in the U.S. and European Union for modulated aspiration in acute ischemic stroke. The device’s design reduces friction between the clot and catheter, potentially speeding up clot removal. Penumbra’s existing data supports its tools for large-vessel occlusions, but the new trial addresses a gap in evidence for M2 blockages.
Related: AdaptHealth patient data stolen in cyberattack
Alex Spiotta, a neurosurgeon at the Medical University of South Carolina and co-principal investigator for the trial, said the study could influence treatment decisions. “The results will help inform physicians on treatment selection for stroke patients with M2 occlusions, potentially supporting wider adoption of mechanical thrombectomy for this challenging condition,” he said in a statement.
The study’s outcomes could reshape clinical guidelines. If Penumbra’s devices prove effective, they might become standard tools for treating M2 occlusions. The research adds to a broader debate about the role of mechanical thrombectomy in stroke treatment, especially for less common blockage types like M2 occlusions, which can be found in the context of patient data and medical records.
Penumbra’s approach is more targeted than previous studies. The company’s trial is designed to provide more specific insights into the effectiveness of mechanical thrombectomy for M2 occlusions.
The trial’s results will depend on factors like patient selection, procedural success rates, and long-term recovery metrics.